

Wakelee, Heather

Institution/Organization

Stanford University and Stanford Cancer Institute

Primary Specialty

Medical Oncology

Annual Disclosures & Policy Agreements

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

COI Policy Review and Compliance

HW

Disclosure of Potential Conflicts

HW

COI Disclosure

Disclosures

AstraZeneca: Advisory board, Institutional, Personal

Janssen Advisory: board Personal

Daiichi Sankyo: Advisory board Personal

Blueprint: Advisory board Personal

Mirati: Advisory role Personal

Helsinn: Advisory role Personal

Fishawack: Facilitate LTD Ongoing series of lectures Personal

Medscape AND Research to Practice AND Curio Science: Multiple CME events Personal

MJH holdings (PER): Multiple CME events/conferences Personal

UpToDate: Royalty payments, Personal

Axis Medical Education and Nexus Oncology: CME events, Personal

ACEA Biosciences: Local PI on trial Institutional

Arrys Therapeutics: Local PI of trial Institutional

BMS (and former Celgene): Local PI of trial and coordinating PI of IIT for former Celgene Institutional

Clovis Oncology: Local PI of trial Institutional

Genentech/Roche: Local PI of trial and Steering Committee Member Institutional

Merck: Local PI of trial and Steering Committee Member Institutional

Novartis: Local PI Institutional

Xcovery: Local PI of trial and Steering Committee Member Institutional

Seagen: Local PI of trial Institutional

COI Disclosure Certification

HW

Confidentiality Agreement

HW

Standards of Conduct Agreement

HW

IASLC's Tax-Exempt Status

HW

COI Follow-Up

Where you have listed larger amounts to institution or personal, are those for clinical trials? If so, how much of the amount is for personal?

Disclose any other board roles or any leadership positions to outside organizations in oncology or research.

Disclose any clinical trials you are conducting for institution fees.

Disclose any other board roles or any leadership positions to outside organizations in oncology or research, such as other oncology societies.

Are you conducting any clinical trials where funds are paid to the institution?

Have you received any personal fees from outside CME companies?

Are you conducting clinical trials with any oncology equipment companies?